<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01948180</url>
  </required_header>
  <id_info>
    <org_study_id>CM-2013-01</org_study_id>
    <nct_id>NCT01948180</nct_id>
  </id_info>
  <brief_title>Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma</brief_title>
  <acronym>CITADEL</acronym>
  <official_title>A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cell Medica Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cell Medica Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients
      with aggressive EBV positive extranodal NK/T-cell lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient enrollment rate
  </why_stopped>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">September 7, 2018</completion_date>
  <primary_completion_date type="Actual">April 16, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as best observed response (complete response or partial response) per Lugano 2014 Disease Response Criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Duration</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunological assessment of EBV-specific T-cell activity and phenotyping</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Monitor levels of plasma and whole blood EBV DNA (viral load)</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Lymphoma, Extranodal NK-T-Cell</condition>
  <condition>EBV</condition>
  <arm_group>
    <arm_group_label>baltaleucel-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment consists of 2 infusions of 2x10E7 cells/m2 given on Days 1 and 15 intravenously via a peripheral or central line over a 1 to 10 minute period.
Subjects who tolerate the study treatment well and who do not require treatment with an alternative chemotherapeutic agent will be eligible for up to 3 additional infusions of 2x10E7 cells/m2 administered at week 8, month 3 and month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>baltaleucel-T</intervention_name>
    <description>Autologous EBV-specific T-cells</description>
    <arm_group_label>baltaleucel-T</arm_group_label>
    <other_name>CMD-003</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        FOR SCREENING PHASE:

        Inclusion Criteria:

          1. Diagnosis of extranodal NK/T lymphoma, per WHO classification, 4th ed., which must
             include EBV tumor positivity, measured either by EBV encoded RNA (EBER) or LMP1
             immunostaining.

          2. a) Active Disease

        (1) Clinically suspected or documented relapse/progression, in first or second relapse
        following at least one cycle of an asparaginase-based chemotherapy regimen OR (2) Initial
        disease or first or second relapse and unable to tolerate one full cycle of
        asparaginase-based chemotherapy regimen OR b) High-risk disease (stage III/IV, KPI groups
        3-4 or IPI intermediate-high) prior to second CR regardless of previous chemotherapy.

        3. Male or female ≥ 18 years of age. 4. Weigh ≥ 35 kg. 5. ECOG performance score 0-2,
        inclusively. 6. Negative β-hCG test in women of childbearing potential. 7. Able to
        understand and comply with the requirements of the study and to provide written informed
        consent.

        Exclusion Criteria:

          1. CNS lymphoma.

          2. NK cell leukemia.

          3. Hemophagocytic lymphohistiocytosis.

          4. Positive for HIV, hepatitis B, hepatitis C, syphilis or human T Cell leukemia virus
             (HTLV).

          5. Use of systemic corticosteroids &gt;0.5 mg/kg/day within 10 days prior to obtaining 200
             mL whole blood starting material.

          6. Patient is pregnant or lactating.

          7. Active second malignancy.

          8. Any prior allogeneic hematopoietic stem cell or solid organ transplant.

          9. Asparaginase refractory disease, defined by any one of the following:

               1. Progression at any time during initial asparaginase based chemotherapy and up to
                  3 months after end of initial asparaginase based chemotherapy, OR

               2. Failure to achieve at least PR with initial asparaginase based chemotherapy.

         10. Absolute lymphocyte count (ALC) &lt;400/µL.

         11. Any previous autologous EBV specific T cell treatment.

         12. Systemic fungal, bacterial, viral or other infection that is not controlled.

         13. Third or greater relapse.

        FOR TREATMENT PHASE:

        Inclusion Criteria:

          1. Documented relapse or progression following at least one prior cycle of an
             asparaginase-containing chemotherapy regimen.

          2. Active disease based on any one of the following present at the baseline study visit
             or within two weeks prior to the baseline study visit:

               1. Imaging (may use local imaging)

               2. Clinical sign(s) including skin lesions consistent with lymphoma, organ
                  dysfunction or organomegaly not attributable to other causes; or other clinical
                  sign(s)

               3. Detectable blood or plasma ENV DNA (may use local laboratory)

          3. Completed most recent course of chemotherapy at least 2 weeks prior to first study
             drug dose.

          4. Recovery from acute hematological, hepatic and renal chemotherapy-related toxicities
             as defined by ≤ Grade 1 according to NCI CTCAE v4.0.

          5. Life expectancy ≥ 8 weeks.

        Exclusion Criteria:

          1. Use of any investigational agents within prior 4 weeks.

          2. Radiotherapy within prior 3 weeks.

          3. Major surgery within prior 2 weeks.

          4. Systemic corticosteroids within 24 hours prior to study drug administration.

          5. Evidence of hepatic dysfunction based on serum total bilirubin &gt;3 times upper limit of
             normal (ULN), or ALT &gt;5 times ULN or AST &gt;5 times ULN.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Heslop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Gunter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cell Medica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ouest</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lyon</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Cancer Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie Clinic</name>
      <address>
        <city>Manchester</city>
        <state>UK</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 13, 2013</study_first_submitted>
  <study_first_submitted_qc>September 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2013</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NKTCL</keyword>
  <keyword>T cell</keyword>
  <keyword>CITADEL</keyword>
  <keyword>Epstein-Barr Virus</keyword>
  <keyword>Natural Killer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 9, 2019</submitted>
    <returned>August 2, 2019</returned>
    <submitted>September 26, 2019</submitted>
    <returned>October 17, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

